About Apellis

By leveraging courageous science, creativity and compassion, we are dedicated to developing potential treatments for patient communities affected by vision loss.

Geographic Atrophy

At Apellis, we’re lighting the way forward

At Apellis, we are fearless in our commitment to addressing the high unmet needs associated with debilitating retinal diseases. We remain steadfast in our mission to develop potential treatments for people with these conditions.
Our journey starts with geographic atrophy.

Given the lack of available approved treatments, geographic atrophy represents the most significant unmet medical need in ophthalmology.1
Complement overactivation is strongly associated with lesion development in geographic atrophy.2
We are dedicated to leading the development of therapies that target the complement system, with the goal of slowing disease progression in geographic atrophy.

Sign up to join us on our journey in geographic atrophy and receive news and updates.

We live by courageous science, creativity and compassion

At Apellis, we strive to be known for our compassion, revolutionary science, and contributions to humankind around the world. Our company is made up of people who care, are fearless in the face of a challenge, love the work they do, and continually pursue the highest level of scientific integrity.

Apellis was established with the ambition to become the first company to develop targeted C3 treatments for serious diseases driven by overactivation of the complement system.


  1. Riquet, D. (n.d.). Parliamentary question | Geographic atrophy as an unmet medical need in the field of ophthalmology | P-000876/2022 | European Parliament. [online] www.europarl.europa.eu. Available at: https://www.europarl.europa.eu/doceo/document/P-9-2022-000876_EN.html. Accessed January 2023.
  2. Katschke, K.J. et al. (2018). Classical and alternative complement activation on photoreceptor outer segments drives monocyte-dependent retinal atrophy. Scientific Reports, [online] 8(1), p.7348. doi:10.1038/s41598-018-25557-8.

EU-CORP-2200001        January 2023

This site uses cookies to store information on your computer.

By clicking “Reject all cookies” only strictly necessary cookies will be used. Kindly be aware that when clicking “Accept all cookies" or choosing to enable performance/analytics cookies, your data will be transferred to the USA. You can always manage and change your cookie settings at any point of time by clicking on our Cookie Statement. Please note that blocking some types of cookies may impact your experience on the site and the services we are able to offer.